Statement by 2016–2017 ASCO President Daniel F. Hayes, MD, FACP, FASCO:
Scott Gottlieb, MD
“The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the U.S. Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in the United States every year, millions of individuals with cancer and their families rely on the FDA to provide critical oversight and evaluation of the safety and efficacy of new medical products as well as those in routine clinical use.
“As a physician and cancer survivor, Dr. Gottlieb knows firsthand that safe and effective cancer treatments must move from the lab to the patient as quickly as possible. We are hopeful that Dr. Gottlieb will serve as a passionate advocate for the public’s health.
We look forward to working with Dr. Gottlieb as we continue to support the FDA in improving the lives of individuals with cancer.— Daniel F. Hayes, MD, FACP, FASCO
“We look to Dr. Gottlieb’s leadership in implementing key provisions of the 21st Century Cures Act that will increase patient access to information about the availability of investigational drugs and allow the FDA to decide how best to use real-world data from clinical practice to support new approvals for drugs already on the market.
“ASCO has a long and productive history of collaborating with the FDA to streamline the approval of new cancer therapies, while ensuring all new treatments are safe and effective. We look forward to working with Dr. Gottlieb as we continue to support the FDA in its important role in reducing cancer incidence, advancing treatment options, and improving the lives of individuals with cancer.”